Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Change in Cash: 2017-2025

Historic Change in Cash for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Sep 2025 value amounting to $57.2 million.

  • Crinetics Pharmaceuticals' Change in Cash rose 278.47% to $57.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$206.4 million, marking a year-over-year decrease of 218.28%. This contributed to the annual value of $209.6 million for FY2024, which is 843.34% up from last year.
  • Crinetics Pharmaceuticals' Change in Cash amounted to $57.2 million in Q3 2025, which was up 239.99% from -$40.8 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' 5-year Change in Cash high stood at $341.0 million for Q1 2024, and its period low was -$170.0 million during Q1 2025.
  • Over the past 3 years, Crinetics Pharmaceuticals' median Change in Cash value was -$1.6 million (recorded in 2023), while the average stood at $7.1 million.
  • Examining YoY changes over the last 5 years, Crinetics Pharmaceuticals' Change in Cash showed a top increase of 3,902.19% in 2024 and a maximum decrease of 5,613.71% in 2024.
  • Crinetics Pharmaceuticals' Change in Cash (Quarterly) stood at $39.2 million in 2021, then slumped by 95.50% to $1.8 million in 2022, then crashed by 5,091.37% to -$87.9 million in 2023, then surged by 40.02% to -$52.7 million in 2024, then spiked by 278.47% to $57.2 million in 2025.
  • Its Change in Cash stands at $57.2 million for Q3 2025, versus -$40.8 million for Q2 2025 and -$170.0 million for Q1 2025.